Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Recombinant gastric lipase - Meristem

Drug Profile

Recombinant gastric lipase - Meristem

Alternative Names: Merispase®; Recombinant gastric lipase

Latest Information Update: 03 Feb 2011

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Meristem Therapeutics
  • Class Carboxylic ester hydrolases
  • Mechanism of Action Lipase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic disorders

Highest Development Phases

  • Discontinued Pancreatic disorders

Most Recent Events

  • 25 Feb 2005 Profile reviewed with information presented at the 3rd Annual BioPartnering North America (BPN-2005)
  • 25 Feb 2005 Recombinant gastric lipase is available for licensing (http://www.meristem-therapeutics.com)
  • 21 Jun 2004 Phase-II clinical trials in Pancreatic disorders in Europe (PO, Capsule)
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top